The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
Abstract
Acetylation of histones leads to conformational changes of DNA. We have previously shown that the histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), induced cell cycle arrest, differentiation, and apoptosis. In addition to their antitumor effects as single agents, HDAC inhibitors may cause conformational changes in the chromatin, rendering the DNA more vulnerable to DNA damaging agents. We examined the effects of SAHA on cell death induced by topo II inhibitors in breast cancer cell lines. Topo II inhibitors stabilize the topo II–DNA complex, resulting in DNA damage. Treatment of cells with SAHA promoted chromatin decondensation associated with increased nuclear concentration and DNA binding of the topo II inhibitor and subsequent potentiation of DNA damage. While SAHA‐induced histone hyperacetylation occurred as early as 4 h, chromatin decondensation was most profound at 48 h. SAHA‐induced potentiation of topo II inhibitors was sequence‐specific. Pre‐exposure of cells to SAHA for 48 h was synergistic, whereas shorter pre‐exposure periods abrogated synergy and exposure of cells to SAHA after the topo II inhibitor resulted in antagonistic effects. Synergy was not observed in cells with depleted topo II levels. These effects were not limited to specific types of topo II inhibitors. We propose that SAHA significantly potentiates the DNA damage induced by topo II inhibitors; however, synergy is dependent on the sequence of drug administration and the expression of the target. These findings may impact the clinical development of combining HDAC inhibitors with DNA damaging agents. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884
Cited by
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Histone Deacetylase Inhibitors: From Bench to Clinic
Paris, M., Porcelloni, M., Binaschi, M., & Fattori, D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7011408 · Cited by 367
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 344
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer
Gridelli, C., Rossi, A., & Maione, P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.002 · Cited by 54
Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside
Hornig, E., Heppt, M. V., Graf, S. A., Ruzicka, T., & Berking, C. (2016) · Experimental Dermatology · doi:10.1111/exd.13089 · Cited by 50
Loh, A. H. P., Stewart, E., Bradley, C. L., Chen, X., Daryani, V., Stewart, C. F., Calabrese, C., Funk, A., Miller, G., Karlstrom, A., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.033 · Cited by 36
Metadata
- Authors
- Marchion, D. C., Bicaku, E., Daud, A. I., Richon, V., Sullivan, D. M., & Munster, P. N.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2004-04-02
- Volume
- 92
- Issue
- 2
- Pages
- 223-237
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2003907016
- Cited by
- 184
- References
- 1
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.